The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2)

<div>The mechanism of action of umifenovir, lopinavir/ritonavir, remdesivir, favipiravir, triazavirin, and hydroxychloroquine in the treatment of SARS-CoV-2-mediated pathophysiology.</div>

BioMed Research International

fig2

Figure 2

Figure 2: The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) 

Figure 2 | The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) 